Therapeutic Target and Cell-signal Communication of Chlorpromazine and Promethazine in Attenuating Blood-Brain Barrier Disruption after Ischemic Stroke.

Ischemic stroke destroys blood-brain barrier (BBB) integrity. There are currently no effective treatments available in the clinical setting. Post-ischemia treatment with phenothiazine drugs [combined chlorpromazine and promethazine (C+P)] has been shown to be neuroprotective in stroke. The present study determined the effect of C+P in BBB integrity. Sprague-Dawley rats were divided into the following groups ( n=8 each): (1) stroke, (2) stroke treated by C+P with temperature control, and (3) stroke treated by C+P without temperature control. Infarct volume and neurological deficits were measured to assess the neuroprotective effect of C+P. BBB permeability was determined by brain edema and Evans blue leakage. Expression of BBB integral molecules, including proteins of aquaporin-4 and -9 (AQP-4, AQP-9), matrix metalloproteinase-2 and -9 (MMP-2, MMP-9), zonula occludens-1 (ZO-1), claudin-1/5, occludin, and laminin were determined by Western blot. Stroke caused brain infarction and neurological deficits, as well as BBB damage, which were all attenuated by C+P through drug-induced hypothermia. When the reduced temperature was controlled to physiological levels, C+P still conferred neuroprotection, suggesting a therapeutic effect independent of hypothermia. Furthermore, C+P significantly attenuated the increase in AQP-4, AQP-9, MMP-2, and MMP-9 levels after stroke, and reversed the decrease in tight junction protein (ZO-1, claudin-1/5, occludin) and basal laminar protein (laminin) levels. This study clearly indicates a beneficial effect of C+P on BBB integrity after stroke, which may be independent of drug-induced hypothermia. These findings further prove the clinical target and cell-signal communication of C+P treatment, which may direct us closer toward the development of an efficacious neuroprotective therapy.

Introduction

The blood–brain barrier (BBB) is composed of endothelial cells interconnected by tight junctions (TJs) and intervening basal lamina (BL), segregating cerebral blood flow from the peripheral circulation to regulate the brain microenvironment[1]. It is well known that ischemic stroke causes brain damage by destroying BBB integrity[2,3]. As a consequence, this altered BBB allows for a stepwise sequence of different edema mechanisms that ultimately leads to BBB leakage[4]. As the BBB plays such a key role in providing selectivity toward the material transferred between the brain parenchyma and bloodstream, its disruption directly relates to negative neurological outcomes. However, no treatment has been proven effective in maintaining the BBB intact after stroke. Our group previously showed that following 2 h ischemia, phenothiazine drugs (chlorpromazine and promethazine (C+P)) reduced brain injury in ischemic rats[5]. However, whether C+P reduces BBB damage remains unknown.

Matrix metalloproteinases (MMPs) and aquaporins (AQPs) are known as important components in the pathophysiology of pan class="Gene">BBB integrity and have become viable candidates for potential pharmacological targets[6,7]. Members of the MMP family, especially MMP-2 and MMP-9, play critical roles in BBB disruption during the acute phase of ischemic stroke[8]. Studies have shown that brain ischemia cleaves the extracellular matrix, including major components of the BL and TJs (claudin-1/5, ZO-1, and occludin) between endothelial cells, by increasing the expression of MMPs that lead to a loss of junctional integrity and BBB disruption[9]. These changes together cause brain vasogenic edema. In addition, the AQP family (known as water channels) has also been proven to play a key role in brain edema progression after stroke by acting as a direct passageway for fluid movement between the brain and blood vessels[10]. Studies have shown that brain ischemia enhanced the expression of AQP-4 and AQP-9 in the edematous rodent brain[11]. Furthermore, our previous studies found an association between infarct volume and AQP-4/AQP-9 expression[12].

Many studies have shown neuroprotective effects when animals with ischemia/reperfusion injury were maintained in a state of hibernation[13]. The “hibernation-like” state with decreased energy utilization by using anesthetics has drawn much interest as a potential neuroprotective stpan class="Species">rategy[13,14]. In our previous studies, hibernation-like therapy with the FDA-approved C+P was proven to be neuroprotective. In the present study, we further determined whether the effects of C+P on infarct volume reduction and neurological deficits were due to reduction in BBB damage and changes in associated molecules, including AQPs, MMPs, and TJs in ischemia/reperfusion injury.

Materials and Methods

Subjects

A total of 120 adult male Sprague-Dawley rats (Vital River Labopan class="Species">ratory Animal Technology Co. Ltd., Beijing, China) were used in this study. An ischemic stroke model was generated by occluding the right middle cerebral artery (MCA) for 2 h. Rats were sacrificed 24 h after reperfusion for edema measurement and 48 h for evaluation of BBB integrity. An additional 24 rats were used for protein expression studies. The animal care and the experiments described here were carried out in agreement with the guidelines set by the Institutional Animal Investigation Committee of the Capital Medical University. Animals were housed under a 12-hour light/dark cycle, and were kept in the same animal care facility for the duration of the study. All efforts were made to minimize any suffering and to reduce the total number of animals used.

Focal Cerebral Ischemia

This model has been described previously by us. Briefly, male Sprague-Dawley rats were initially anesthetized in a chamber with 1–3% isoflurane along with a mixture of 70% nitrous oxide and 30% oxygen. The rats were transferred to a surgical table and anesthesia was maintained with a facemask using 1% isoflurane delivered from a calibrated precision vaporizer. Poly-L-lysine-coated intraluminal nylon (4.0) sutures were used to occlude the MCA and yield consistent infarcts and greatly reduce inter-animal variability.

Chlorpromazine and Promethazine Administration

In 2 h MCA occlusion with reperfusion, the combination of chlorpromazine and pan class="Chemical">promethazine (1:1) at doses of 8 mg/kg in 3 ml saline (as determined by a preliminary study to induce significant neuroprotection) was injected IP at 2 h after the onset of ischemia. A second injection with one-third of the original dose was added 1–2 h later to enhance the drugs’ effects. Two sets of animals were used: one with body temperature maintained at physiological levels (rectal temperature at 36.5–37.5°C) and one without body temperature control. Because of the close correlation between body and brain temperatures[15] and increased risk of intracranial hemorrhage, rectal temperature was monitored instead of brain temperature. During the recovery period (24–28 h), in all temperature-controlled groups, rats were placed on a 37°C insulation blanket as well as under a warm light to maintain their temperature. In groups without temperature control, rats were placed in a 25°C environment.

Neurological Deficit

The modified scoring systems (5 and 12 scores) proposed by Longa et al.[16] and Belayev et al.[17] were used to examine the severity of neurological deficits in rats before surgery, during MCA occlusion, and after 24 h reperfusion. The severity of brain damage and consistency in each group are highly important in this study. After MCA occlusion, the modified scoring systems (five scores) for neurological deficits were used to confirm brain injury. If the scores were 1 or below, the MCA occlusions were considered unsuccessful and the rats were excluded from further studies. In our study, about 10% of animals with MCA occlusion were discarded for this reason.

Cerebral Infarct Volume

After 24 h of reperfusion in rats with 2 h MCA occlusion, the brains were resected from ischemic rats and cut into 2 mm-thick slices (brain matrix) and treated with 2, 3, 5- triphenyltetrazolium chloride (TTC, Sigma, St. Louis, MO, USA) for staining. An indirect method for calculating infarct volume was used to minimize error caused by edema. We also measured and compared infarct size of the cortex and striatum at three different levels from anterior +1.00 mm to posterior –4.8 mm to the bregma of the brain[18].

Brain Edema and Brain Barrier Integrity Measurements

Brain edema was evaluated through measurements of tissue pan class="Chemical">water content. Following animal sacrifice, separated right and left hemispheres were immediately weighed to obtain wet weight (WW). The tissue was then dried in an oven at 70°C for 72 h and weighed again to obtain the dry weight (DW). The formula (WW–DW)/WW×100% was used to calculate the water content and is expressed here as a percentage of WW. BBB permeability was determined by measuring the amount of Evans blue extravasation from the ipsilateral and contralateral hemispheres of the brain. Evans blue dye (2%, 4 ml/kg body weight) was slowly administered intravenously 46 h after reperfusion and allowed to circulate for 2 h. The rats were then perfused with normal saline to wash away any remaining dye in the blood vessels, and the two hemispheres of the brain were dissected and frozen at –80°C for later analysis. The Evans blue dye was extracted from tissues by homogenizing and incubating the samples in 2 ml formamide at 54°C for 2 h. The solutions were then centrifuged for 15 min at 12,000 g. The absorption of each supernatant was measured at 620 nm with a spectrophotometer (Agilent/HP 8453, Agilent/HP, San Diego, CA, USA). The content of Evans blue in each sample was expressed as μg/g of brain tissue using a standardized curve[19].

Protein Expression

Western blot analysis was used to detect protein expression in the ischemic tissue, as described previously[18]. Protein extracted from pan class="Species">rat brain isolates in the control group and C+P treatment groups with or without temperature control was loaded onto gel for electrophoresis. Upon conclusion of electrophoresis, proteins were transferred to a polyvinylidene fluoride membrane. Membranes were incubated with a primary antibody (rabbit anti-rat MMP-2 antibody, 87809, CST; rabbit anti-rat MMP-9 antibody, AV33090, (Sigma); rabbit anti-rat AQP-4, HPA014784, (Sigma); rabbit anti-rat AQP-9, sc-28623, (Santa Cruz, Dallas, TX, USA); rabbit anti-rat claudin-1, SAB4503545, (Sigma); rabbit anti-rat claudin-5, SAB4502981, (Sigma); rabbit anti-rat occludin, sc-5562, (Santa Cruz); rabbit anti-rat ZO-1, sc-10804, (Santa Cruz)) for 24 h at 4°C. Next, membranes were washed three times with phosphate-buffered saline for 6 minutes each, and re-incubated with a secondary antibody (goat anti-rabbit IgG, (Santa Cruz)) for 1 h at room temperature. An enhanced chemiluminescence system was used to detect immune-reactive bands by luminescence. Western blot images for each antibody, including β-actin, were analyzed using an image analysis program (Image J 1.42, National Institutes of Health, USA) to quantify protein expression in terms of relative image density. The mean amount of protein expression from the control group after stroke was assigned a value of 1 to serve as reference.

Statistical Analysis

Statistical analysis was performed with SPSS for Windows, version 17.0 (SPSS, Inc., Chicago, IL, USA). The differences among groups were assessed using one-way ANOVA with a significance level at P<0.05. Post hoc comparison among groups was further performed using the least significant difference.

Results

Physiological Parameters

There were no significant differences in blood pH, pO2, pCO2, or blood glucose between the groups (data not shown).

Body Temperature

In wild-type (data not shown) or 2 h MCA occlusion rats, body temperatures were significantly reduced by 1–2°C after C+P administration, with 8 mg/kg doses achieving this value within as early as 5 min (Fig. 1A). At about 2 h after administration, body temperatures reached 33–34°C. These temperatures remained significantly low for up to 6 h and subsequently returned to normal levels.

Fig. 1.

(A) In 2 h MCA occlusion groups, body temperatures (n=8 per group) were measured in a time-dependent manner. ANOVA analyses indicated that C+P significantly (##P<0.01) reduced body temperature as early as within 5 min and lasting up to 12 h after stroke onset. (B) Infarct volume reduction by drug-induced hypothermia from C+P. TTC histology demonstrating infarct volume reduction in the penumbra region of ischemic territory supplied by MCA with C+P± temperature control after 2 h MCA occlusion. (C) Quantification of infarct volume reduction by C+P. Treatments without temperature control were allowed to reach drug-induced hypothermia as indicated in Fig. 1A and demonstrated slightly greater but not significant infarct volume reduction than subjects maintained at 37°C.

Infarct Volume

A large infarct volume (50.3%) was seen after 2 h MCA occlusion and 48 h reperfusion. The 8 mg/kg doses of C + P significantly (#p<0.05) decreased infarct volumes (35.7%) when body temperatures were maintained at 37°C (Fig. 1B, C). If body temperature was not controlled and allowed to reach a hypothermic state after C+P administration, brain infarct volumes were slightly (#p<0.05) further reduced further (29.8 vs. 35.7%).

Neurological Deficits

Neurological deficits were detected 24 h after reperfusion, determined by the 5 (Fig. 2A) or 12 (Fig. 2B) score systems. Compared with no treatment stroke groups, neurological deficits were decreased significantly with or without temperature control.

Fig. 2.

Neurological deficits after C+P therapy with or without body temperature control in 2 h MCA occlusion, using the 5 score system (A) and 12 score system (B). ANOVA analyses indicated that both C+P therapy with no temp control (##p<0.01) or temp control (#p<0.05) reduced neurological deficits.

Neurological deficits after C+P therapy with or without body tempepan class="Species">rature control in 2 h MCA occlusion, using the 5 score system (A) and 12 score system (B). ANOVA analyses indicated that both C+P therapy with no temp control (##p<0.01) or temp control (#p<0.05) reduced neurological deficits.

Brain Edema and BBB Integrity

Brain edema was quantified 24 h after reperfusion was established (Fig. 3A). On the ipsilateral side, a significant (**p<0.01) increase in pan class="Chemical">water content was observed in ischemic rats (84.9%), as compared with control rats (74.8%). C+P treatment significantly (##p<0.01) reduced tissue water content with no temperature control (79.5%) or with temperature control (79.9%). C+P treatment made no significant difference to the water levels when compared with the control group in the contralateral hemisphere of ischemic rats. BBB permeability was quantified by Evans blue dye extravasation at 48 h after reperfusion (Fig. 3B). On the ipsilateral side, a significant (**p<0.01) increase in BBB permeability was observed in ischemic rats (9.3 μg/g), as compared with control rats (1.8 μg/g). C+P treatment reduced (##p<0.01) tissue water content under either hypothermia (2.2 μg/g) or normothermia (4.5 μg/g). C+P treatment made no significant difference to the BBB permeability when compared with the control group in the contralateral hemisphere of ischemic rats.

Fig. 3.

C+P reduced brain edema and BBB leakage. (A) C+P treatment attenuated ipsilateral stroke-induced brain edema significantly versus ipsilateral stroke group without treatment (##P<0.01). (B) C+P reduced BBB leakage significantly on the ipsilateral side in comparison to the ipsilateral stroke group without treatment (##p<0.01), but unrelated to temperature.

Expression of AQP-4/9 and MMP-2/9

Ischemic rats with 2 h MCA occlusion showed a significant (*p<0.05) increase in MMP-2 and MMP-9 levels at 6 and 24 h of reperfusion. Compared with stroke groups without treatment, levels of MMP-2 (1.2 vs. 1.8 at 6 h, #p<0.05; 1.4 vs. 2.0 at 24 h, #p<0.05, Fig. 4A) and MMP-9 (1.1 vs. 1.5 at 6 h, #p<0.05; 1.1 vs. 2.1 at 24 h, #p<0.05, Fig. 4B) in C+P treatment without temperature control groups were significantly decreased. Although the mechanism of why the MMP-2 level at 6 h was slightly higher than that at 24 h with C+P treatment without temperature control is not clear, it suggests that the most vigorous action of MMP-2 was at the early stage and might be the best time-point for C+P targeted therapy. Similar levels of MMP-2 (0.7 vs. 1.8 at 6 h, ##p<0.01; 1.8 vs. 2.0 at 24 h, Fig. 4A) and MMP-9 (1.2 vs. 2.1 at 24 h, #p<0.05 Fig. 4B) reduction were also found in C+P treatment with temperature control groups.

Fig. 4.

C+P downregulated MMP-2 and MMP-9 expression. (A) MMP-2 protein expression was significantly decreased by C+P with or without temperature control as compared with stroke groups without treatment at 6 h after reperfusion. A decrease in MMP-2 expression was slightly seen at 24 h by C+P. (B) MMP-9 protein expression was significantly increased after stroke and was reversed by C+P without temperature control at 6 h (#p<0.05) and 24 h (#p<0.05) after reperfusion. C+P with temperature control at 37°C decreased MMP-9 expression only at 24 h (#p<0.05). Representative immunoblots are presented.

Similarly, AQP-4 and AQP-9 levels were largely increased in ischemic rats at 6 h (**p<0.01), suggesting decreased BBB integrity. Levels of both AQP-4 (0.6 vs. 1.3 at 6 h, ##p<0.01; 0.7 vs. 0.9 at 24 h, Fig. 5A) and AQP-9 (1.0 vs. 1.6 at 6 h, ##p<0.01; 1.2 vs. 2.0 at 24 h, #p<0.01, Fig. 5B) were significantly decreased by C+P without temperature control groups. Similar levels of AQP-4 (0.3 vs. 1.3 at 6 h, ##p<0.01; 0.7 vs. 0.9 at 24 h, Fig. 5A) and AQP-9 (1.4 vs. 1.6 at 6 h; 1.1 vs. 2.0 at 24 h, #p<0.05 Fig. 5B) reduction were also found in C+P treatment with temperature control groups.

Fig. 5.

Stroke upregulated AQP-4 and AQP-9 expression. (A) AQP-4 protein expression was significantly decreased by C+P with or without temperature control as compared with stroke groups without treatment at 6 h (significantly, ##p<0.01) and 24 h (slightly) after reperfusion. (B) AQP-9 protein expression was significantly increased after stroke and reduced by C+P without temperature control at 6 h (##p<0.01) and 24 h (#p<0.05) after reperfusion. Similarly, a decrease in AQP-9 expression after stroke was induced by C+P with temperature control at 6 (slightly) and 24 h (significantly, #p<0.05). Representative immunoblots are presented.

Basal Lamina and Tight Junction Protein Expression

To test whether C+P treatment after stroke might influence BBB integrity, the expressions of claudin-1, claudin-5, occludin, zonula occludens (ZO)-1, and laminin were assessed. Compared with the sham-operated group referenced as 1, ischemia and reperfusion decreased protein expression of laminin, claudin-1, claudin-5, occluding, and ZO-1 (Fig. 6). Levels of claudin-1 (1.2 vs. 0.8 at 6 h; 1.1 vs. 0.9 at 24 h, Fig. 6A), claudin-5 (0.7 vs. 0.3 at 6 h, ##p<0.01; 1.0 vs. 0.6 at 24 h, #p<0.05, Fig. 6B), occludin (1.0 vs. 0.9 at 6 h; 1.0 vs. 0.6 at 24 h, #p<0.05, Fig. 6C), ZO-1 (0.9 vs. 0.7 at 6 h; 0.9 vs. 0.6 at 24 h, #p<0.05, Fig. 6D) and laminin (1.1 vs. 0.7 at 6 h; 1.1 vs. 0.3 at 24 h, #p<0.05, Fig. 6E) were significantly increased by C+P, most likely without temperature control.

Fig. 6.

(A) Claudin-1 protein expression was slightly increased with C+P as compared with stroke groups without treatment at 6 and 24 h after reperfusion. (B) A significant decrease in claudin-5 protein expression was seen after stroke, and this decrease was reversed by C+P± temperature control at 6 (##p<0.01) and 24 h (#p<0.05). Occludin protein expression (C) and ZO-1 protein expression (D) were increased by C+P without temperature control but not with temperature control as compared with stroke groups without treatment at 6 (slightly) and 24 h (significantly, #p<0.05) after reperfusion. (E) Laminin protein expression was increased by C+P with or without temperature control compared to stroke groups at 6 (slightly) and 24 h (significantly, #p<0.05) after reperfusion. Representative immunoblots are presented.

(A) Claudin-1 protein expression was slightly increased with C+P as compared with pan class="Disease">stroke groups without treatment at 6 and 24 h after reperfusion. (B) A significant decrease in claudin-5 protein expression was seen after stroke, and this decrease was reversed by C+P± temperature control at 6 (##p<0.01) and 24 h (#p<0.05). Occludin protein expression (C) and ZO-1 protein expression (D) were increased by C+P without temperature control but not with temperature control as compared with stroke groups without treatment at 6 (slightly) and 24 h (significantly, #p<0.05) after reperfusion. (E) Laminin protein expression was increased by C+P with or without temperature control compared to stroke groups at 6 (slightly) and 24 h (significantly, #p<0.05) after reperfusion. Representative immunoblots are presented.

Discussion

In this study, we found that C+P in hypothermic or normothermic conditions can reduce infarct volume, improve functional neurological deficits, decrease brain edema, and attenuate BBB breakdown after cerebral ischemia in the rat. In addition, gap formations within the endothelial cell layer of the BBB were induced in the ischemic brain, and TJ proteins (including claudin-1, claudin-5, occluding, and ZO-1) were significantly increased after C+P treatment, along with induced expression levels of laminin and BBB integral proteins (including MMP-2, MMP-9, AQP-4, and AQP-9). Our study illustrates the influence of C+P on the brain’s microvascular system, with the results suggesting that C+P induces neuroprotection by improving microvascular integrity and reinforcement of the BL.

C+P, classical members of the phenothiazine drugs, have been widely used as neuroleptics since the 1950s. These two drugs, usually used in combination, are two of the oldest and most-studied drugs from the pan class="Chemical">phenothiazine class. Because of their high lipophilicity, C+P can easily pass through the BBB to exert their depressive metabolic effects. We have previously reported an “artificial hibernation” effect of alcohol on the brain for suppressing metabolism that leads to neuroprotection following the onset of ischemic stroke. However, in comparison to C+P, there are many societal implications and side effects associated with alcohol which may limit its clinical translation. In addition to their clinical use for their antipsychotic and sedative effects, the present experimental studies along with previous studies support a new application of C+P as neuroprotectants in stroke for their ability to induce an “artificial hibernation” status.

Phenothiazines, specifically pan class="Chemical">chlorpromazine and promethazine, have shown promise as drugs that could be repurposed to treat victims suffering from ischemic stroke. They hold the capacity of suppressing free radicals, reducing the uptake of Ca2+ and K+ leakage by plasma membrane, inhibiting the swelling of cells, and preventing the release of acidic hydrolyses. It has been demonstrated that phenothiazines protect the membrane by inhibiting phospholipase activation[20]. In addition, phenothiazines could slow down metabolism by uncoupling oxidative phosphorylation via inhibition of glucose oxidation[20]. The ability to decrease glucose utilization and uptake suggests that the target of these drugs involves the transport pathway. The mechanism is still debated, but it has been shown that these drugs have a marginal effect as antagonists on dopaminergic receptors (D2 dopamine receptors) and mediate the reduced uptake of glucose. Because of their marginal effect, it was also hypothesized that these drugs act on Ca2+ channels[21]. It has been reported that phenothiazines could inhibit apoptosis, reducing activation of caspases and cytochrome c release from mitochondria, which are most likely a result of protecting the mitochondria membrane from reactive oxygen species (ROS) and lipases that try to disrupt it[22]. When treated with promethazine and chlorpromazine, free radical-induced lipid peroxidation was significantly reduced in rats[20]. In addition, once phenothiazines were administered, cerebral blood flow was markedly reduced, and oxygen consumption was consequently reduced as well[23].

TJs participate in forming the BBB and are composed of pan class="Gene">occludin (one of the transmembrane proteins), ZO-1 (an accessory cytoplasmic protein), and claudins (the key integral proteins), all of which play important roles in regulating BBB permeability and function[24]. Shi et al thought that blood occludin could be a clinically viable biomarker for evaluating BBB damage during ischemia/reperfusion in patients, which put forward the clinical significance of occludin on the BBB[25]. The disruption of occludin led to functional changes of the TJs in rats[26,27] and was associated with hypoxia-induced vascular leakage[28]. The protective effects of occludin on BBB integrity, however, are not sufficiently understood. It was reported in an in vitro study that the activation of hypoxia-inducible factor-1α (HIF-1α) could lead to lower protein levels of occludin, resulting in an increase in BBB permeability[29,30]. HIF-1α regulates many kinds of protein expression in response to various pathophysiological conditions induced by hypoxia[31], which may potentially explain the effect of occludin on BBB damage. In addition, by using lipopolysaccharide-induced dysregulation of the TJ, Qin et al. proposed another idea—activation of MMP-2 through augmenting the p38MAPK/JNK signaling pathways may be another way to cause occludin dysregulation in the BBB[32].

Moreover, ZO-1 was found to be reduced after ischemic stroke, which was confirmed to be related to the functional changes in TJs[33]. The protective effects of ZO-1 on BBB integrity are various. It was reported that the EGFR-ERK1/2 pathway consists of key signaling proteins that regulate ZO-1 expression, which directly affects BBB permeability[34]. Recently, studies have also shown that Ras signaling induces the generation of ROS via activating the downstream effector mitogen-activated protein kinase (MEK)/extracellular signal regulated kinases (ERK), resulting in the alteration of TJs and BBB permeability. Jiang et al. reported that ZO-1 could be induced in brain endothelial cells via the Ras signaling pathway, which suggests another form of regulation for ZO-1[35]. Furthermore, through an in vivo experiment, Zhang et al. demonstrated that enhanced autophagy could cause ZO-1 reduction and result in increasing BBB permeability, providing new insights into targeting ZO-1 regulation[8].

Claudin is another class of TJs found to be decreased in lesioned vessels with BBB breakdown in the pan class="Disease">ischemic brain. When claudin-5[36,37] or claudin-1[38] expression is increased, BBB permeability is decreased. It was reported that vascular endothelial cadherin can upregulate claudin expression by preventing the nuclear accumulation of the transcriptional regulator forkhead box O1 (FoxO1)[39]. Our previous study had also confirmed that FoxO1 is regulated by HIF-1α, which is induced by ischemia. The HIF-1α-FoxO1 pathway may be the main signaling mechanism that regulates claudin expression in maintaining BBB integrity. In addition, increased transforming growth factor-β (TGF-β) was shown to decrease the activity of claudin, which compromises the integrity of endothelial sheets[40]. Claudin can also be modified by cyclic adenosine monophosphate (cAMP) via PKA-induced phosphorylation[41] and mediated at Thr207 by Rho/ Rho kinase (RhoK) signaling via a PKA-independent pathway, resulting in phosphorylation and redistribution of claudin and ultimately in increased BBB permeability[42].

Laminin, on the other hand, acts as a major structural protein of the BL and is known to be involved with BBB pathology[43,44]. It was reported that laminin regulates the matupan class="Species">ration and function of the BBB, maintains BBB integrity, and regulates ventricular size or development[43]. Laminin may alleviate vasogenic edema through promoting migration of astrocytes to damaged or newly generated vessels to repair BBB disruption and reconstruction of the endothelial barrier[45].

Recent studies have demonstrated a rapidly marked increase in the expression of pan class="Gene">MMP-2/9 at the site of ischemia, and occludin proved to be a direct substrate of MMPs after ischemic stroke[46]. The formation of vasogenic edema has been linked to the activation of MMPs, which are associated with BBB degradation and increased permeability/leakage[47,48]. Several studies have shown a significant increase in ROS leakage during reperfusion with BBB disruption[49]. The elevation in ROS contributes to the destabilization of the BBB by upregulating ERK1/2, which activates the NF-κB transcription factor. Activated NF-κB in turn activates the transcription of the MMP-9 gene to result in BBB damage[50,51]. Meanwhile, our previous study had reported that limb ischemic preconditioning can attenuate BBB disruption by decreasing ERK1/2 phosphorylation, therefore C+P treatment has the potential to inhibit MMP-9 regulated by the ERK1/2- NF-κB pathway. In addition, Machida et al. found the effect of thrombin-PAR1-PKCθ/δ axis on MMP-9-induced BBB leakage[52]. The protein kinase C (PKC) family is associated with TJ and cytoskeletal reorganization, endothelial barrier dysfunction, apoptosis, oxidative stress, and MMP production. Current evidence reveals that PKC-α and PKC-β isoforms play pivotal roles in TNF-α-mediated endothelial barrier dysfunction via regulation of MMP-2[53]. In this study, our data suggest that the use of C+P can suppress brain edema by inhibiting MMP-2 or MMP-9. Combined with our previous study finding that C+P exert neuroprotective effects after ischemia by decreasing protein expression of PKC, we hypothesize that PKC may be a key protein for C+P regulation of MMPs in brain edema. Furthermore, another study drew the conclusion that MMP-2/9 activities can lead to decreases in TJ (claudin-5 and occludin) protein levels through the p38MAPK/JNK signaling pathways[32].

Recent studies have suggested aquaporins as another molecular mechanism for edema formation in the pan class="Gene">BBB[10,11]. It has been reported that AQP-4 plays a vital role in brain edema[10], but some studies indicated that AQP-4 expression does not alter BBB integrity[54]. There is no BBB alteration in AQP-4 knockout mice, suggesting no relationship between AQP-4 and BBB function. In our study, our data were consistent with the notion that the decrease in AQP-4 expression induced cerebral edema, not by directly contributing to BBB breakdown, but via transcellular water channels. The use of C+P suppressed brain edema by inhibiting AQP-4 or AQP-9. These results suggest that increased AQP expression in brain tissues can generate and exacerbate edema by upregulation of the water channel. Cytotoxic edema occurs rapidly and can persist 24 h after MCA occlusion[55]. Oxygen-glucose deprivation disrupts the self-regulation of neurons and astrocytes, producing an ionic gradient that allows uncontrolled influx of water through AQP channels due to osmotic pressure[56] and leading to an obvious increase in intracellular fluid volume. When edema occurs, astrocyte swelling is more obvious than neuronal swelling because of astrocyte potassium spatial buffering and glutamate uptake, which causes osmotic overload of brain cells and the subsequent influx of water. The overexpression of AQPs in astrocytic end-feet also contributes to cytotoxic edema-induced apoptosis[57], which results in BBB damage and eventual hemorrhagic transformation after reperfusion[58]. Furthermore, both AQP-4 and AQP-9 upregulation has been shown to potentiate brain edema after ischemic stroke by allowing increased water transport between fluid compartments through the BBB.

The protective mechanisms of C+P on BBB integrity are poorly understood. It has been shown that the TJs’ integrity is associated with HIF-1α, which may potentially explain the improvement in pan class="Gene">BBB integrity with C+P. Many studies have shown HIF-1α to be upregulated in traumatic brain injury models, and our previous study also showed that inhibition of HIF-1α causes increased expression of both BBB BL and TJ proteins[59]. This inhibition produced the opposite effect in AQP-4 and MMP-9 expression, suggesting that HIF-1α is a key protein in the formation of brain edema. Recent studies have demonstrated that HIF-1α and its target genes may contribute to cell death, tissue destruction, and the formation of brain edema primarily in the acute phase after ischemic brain damage, suggesting that inhibition of HIF-1α is likely to be beneficial during the acute phase[60]. In addition, FoxO1 was reported to have functions regulating claudin-5 in endothelial cells, which might be crucial for maintaining brain microvascular endothelial cell integrity[61]. In agreement with this, an accumulation of FoxO1 transcriptional activity was observed in the brain, correlating with the enhancement of BBB leakage[62]. In addition, the activation of HIF-1α, which could lead to upregulation of many genes involved in the recruitment, adhesion, and activation of leukocytes, may create a feedback loop enhancing BBB vascular damage[63,64]. HIF-1α has also been reported to play a critical role in regulating the interaction of FoxO1 in the pathogenesis of BBB breakdown[65]. Therefore, we will further determine the potential mechanism underlying the HIF-1α-FoxO1 signaling pathway in C+P induced neuroprotection in our future study.

In conclusion, the present study demonstrated a pathway involving pan class="Gene">claudin-1/5, occludin, ZO-1, laminin, MMP-2, MMP-9, AQP-4, and AQP-9 in brain edema formation and BBB disruption after ischemic stroke, and its improvement with C+P. Elucidation of the pathway can provide insights into effective pharmacological target therapies. To our knowledge, this is the first study to show the effect of C+P on MMPs, AQPs, and TJs leading to edema formation. In addition, C+P readily cross the BBB and easily diffuse through the collateral circulation into ischemic regions before reperfusion is even established. The clinical potential as stroke therapeutics of this widely available FDA-approved drug is apparent. Future studies of C+P in a clinical setting may move us closer toward the development of an efficacious neuroprotective therapy.